{"nct_id":"NCT05609968","title":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2023-02-06","start_date_type":"ACTUAL","primary_completion_date":"2027-01-12","primary_completion_date_type":"ESTIMATED","completion_date":"2028-08-23","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}